The global market for Urinary Tract Infection Treatment was estimated at US$10.7 Billion in 2023 and is projected to reach US$12.7 Billion by 2030, growing at a CAGR of 2.5% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Quinolones segment, which is expected to reach US$5.2 Billion by 2030 with a CAGR of a 2.3%. The ß-lactam segment is also set to grow at 3.2% CAGR for the next 7-year period.
- Regional Analysis: Gain insights into the U.S. market, which was estimated at $2.9 Billion in 2023, and China, forecasted to grow at an impressive 3.9% CAGR to reach $2.4 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Urinary Tract Infection Treatment Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Urinary Tract Infection Treatment Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Urinary Tract Infection Treatment Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of major players such as Allergan PLC, AstraZeneca PLC, Bayer AG, and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Select Competitors (Total 41 Featured):
- Allergan PLC
- AstraZeneca PLC
- Bayer AG
- Johnson & Johnson
- Lipella Pharmaceuticals Inc.
- Merck & Co., Inc.
- MerLion Pharmaceuticals GmbH
- Mylan Pharmaceutical Pvt. Ltd.
- Novartis AG
- Novo Nordisk A/S
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
- Urigen Pharmaceuticals, Inc.
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIII. MARKET ANALYSISSOUTH KOREAREST OF ASIA-PACIFICARGENTINABRAZILMEXICOREST OF LATIN AMERICAIRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EASTIV. COMPETITION
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
CANADA
JAPAN
CHINA
EUROPE
FRANCE
GERMANY
ITALY
UNITED KINGDOM
SPAIN
RUSSIA
REST OF EUROPE
ASIA-PACIFIC
AUSTRALIA
INDIA
LATIN AMERICA
MIDDLE EAST
AFRICA
Companies Mentioned
- Allergan PLC
- AstraZeneca PLC
- Bayer AG
- Johnson & Johnson
- Lipella Pharmaceuticals Inc.
- Merck & Co., Inc.
- MerLion Pharmaceuticals GmbH
- Mylan Pharmaceutical Pvt. Ltd.
- Novartis AG
- Novo Nordisk A/S
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
- Urigen Pharmaceuticals, Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 194 |
| Published | December 2024 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 10.7 Billion |
| Forecasted Market Value ( USD | $ 12.7 Billion |
| Compound Annual Growth Rate | 2.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 13 |
